Apogee Therapeutics, Inc. (Nasdaq: APGE) announced the pricing of its public offering, expecting to raise approximately $300 million. The offering includes common stock and pre-funded warrants. Jefferies, BofA Securities, Guggenheim Securities, TD Cowen, and BTIG are acting as book-running managers. The offering is expected to close on October 10, 2025, subject to closing conditions. Apogee is a biotechnology company focusing on inflammatory and immunology markets, with programs targeting Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and more. The company aims to deliver value and benefit to underserved patients through its antibody programs.

The offering is being made through a written prospectus and is subject to SEC regulations. Apogee’s most advanced program, APG777, is designed for the treatment of Atopic Dermatitis. The company’s pipeline includes four validated targets with a focus on achieving best-in-class profiles through novel antibodies. Forward-looking statements in the press release highlight the potential value of the company’s product candidates and the risks associated with clinical trials and regulatory approvals. Investors and media can contact the company for more information on the offering and programs.

Read more at GlobeNewswire: Apogee Therapeutics, Inc. Announces Pricing of $300 Million